Safety and Efficacy Study of Fostamatinib to Treat Immunoglobin A (IgA) Nephropathy

Status:
Completed

Trial end date:
2018-11-12

Target enrollment:

Participant gender:

The purpose of this study is to determine whether fostamatinib is safe and effective in the treatment of IgA Nephropathy

Phase 2

Rigel Pharmaceuticals